Author:
Willemsen R.,Tibbe J. J. M.,Kroos M. A.,Martin B. M.,Reuser A. J. J.,Ginns E. I.
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. barneveld,r. a.,tegelaers,f. p.,ginns,e. i.,visser,p.,laanen,e. A.,brady,r. o.,galjaard,h.,barranger,j. a.,reuser,a. j. j. &tager,j. m. (1983a) Monoclonal antibodies against human betaglucocerebrosidase.Eur. J. Biochem. 134, 585–89.
2. barneveld,r. a.,keijzer,w.,tegelaers,f. p.,ginns,e. i.,geurts van kessel,a.,brady,r. o.,barranger,j. a.,tager,j. m.,galjaard,h.,westerveld,a. &reuser,a. J. J. (1983b) Assignment of the gene coding for human β-glucocerebrosidase to the region 921–q31 of chromosome 1 using monoclonal antibodies.Hum. Genet. 64, 227–31.
3. barranger,j. a. &ginns,e. i. (1989) Glucosylceramide lipidoses: Gaucher disease. InThe Metabolic Basis of Inherited Disease (edited byscriver,c. r. et al.), pp. 1677–98. New York: McGraw-Hill.
4. barton,n. w.,brady,r. o.,dambrosia,j. m. &dibisceglie,a. m. (1991) Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher disease.N. Engl. J. Med. 324, 1464–70.
5. beutler,e.,dale,g. l. &kuhl,w. (1980) Replacement therapy in Gaucher disease. InEnzyme Therapy in Genetic Diseases (edited bydesnick,r. j.) Vol. 2, pp. 369–81. New York: Alan R. Liss.